These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19106609)

  • 1. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.
    Rexer BN; Engelman JA; Arteaga CL
    Cell Cycle; 2009 Jan; 8(1):18-22. PubMed ID: 19106609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
    Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
    J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
    Ni L; Nie L
    Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR-TKIs resistance via EGFR-independent signaling pathways.
    Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
    Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
    Liao BC; Lin CC; Lee JH; Yang JC
    J Biomed Sci; 2016 Dec; 23(1):86. PubMed ID: 27912760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
    Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.
    Jaiswal BS; Durinck S; Stawiski EW; Yin J; Wang W; Lin E; Moffat J; Martin SE; Modrusan Z; Seshagiri S
    Clin Cancer Res; 2018 Aug; 24(16):4044-4055. PubMed ID: 29760222
    [No Abstract]   [Full Text] [Related]  

  • 10. EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
    Rose M; Maurer A; Wirtz J; Bleilevens A; Waldmann T; Wenz M; Eyll M; Geelvink M; Gereitzig M; Rüchel N; Denecke B; Eltze E; Herrmann E; Toma M; Horst D; Grimm T; Denzinger S; Ecke T; Vögeli TA; Knuechel R; Maurer J; Gaisa NT
    Oncogene; 2020 Oct; 39(44):6856-6870. PubMed ID: 32978523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
    Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
    Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Wang W; Li Q; Yamada T; Matsumoto K; Matsumoto I; Oda M; Watanabe G; Kayano Y; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2009 Nov; 15(21):6630-8. PubMed ID: 19843665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
    Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
    Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
    Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
    Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
    Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations.
    Pallis A; Briasoulis E; Linardou H; Papadimitriou C; Bafaloukos D; Kosmidis P; Murray S
    Curr Med Chem; 2011; 18(11):1613-28. PubMed ID: 21428885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.